Regeneron Pharmaceuticals Inc (REGN)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 77.27% | 77.49% | 77.41% | 77.53% | 78.23% | 59.09% | 58.20% | 58.47% | 59.06% | 82.66% | 83.97% | 85.83% | 85.72% | 89.30% | 89.56% | 88.18% | 87.67% | 87.29% | 85.72% | 84.77% |
| Operating profit margin | 28.13% | 28.77% | 29.06% | 29.56% | 31.03% | 32.41% | 34.39% | 35.97% | 39.12% | 45.64% | 48.37% | 55.27% | 55.87% | 55.36% | 54.18% | 43.61% | 42.30% | 37.62% | 34.74% | 30.53% |
| Pretax margin | 33.69% | 35.98% | 34.14% | 31.02% | 32.19% | 33.60% | 37.90% | 37.83% | 40.11% | 44.22% | 44.77% | 55.52% | 58.23% | 59.61% | 58.63% | 48.05% | 45.07% | 42.38% | 40.70% | 32.06% |
| Net profit margin | 31.11% | 33.70% | 32.16% | 29.61% | 30.31% | 30.64% | 34.12% | 33.99% | 35.81% | 39.33% | 40.13% | 48.22% | 50.43% | 51.82% | 50.33% | 43.77% | 41.55% | 38.48% | 37.41% | 28.64% |
Regeneron Pharmaceuticals Inc's profitability ratios have shown some fluctuations over the periods analyzed.
1. Gross Profit Margin: The company's gross profit margin has generally been high, ranging from 83.97% to 89.56%. However, there was a notable decrease in the margin to 59.06% by December 31, 2022, before recovering to 78.23% by December 31, 2023.
2. Operating Profit Margin: Over the periods, the operating profit margin started at 30.53% on March 31, 2020, increased significantly to 55.87% by December 31, 2021, and then saw a downward trend, reaching 28.13% by December 31, 2024.
3. Pretax Margin: The pretax margin also experienced fluctuations, with a peak at 59.61% on September 30, 2021, followed by a decline to 28.13% by December 31, 2024.
4. Net Profit Margin: The net profit margin ranged from 29.61% to 51.82% over the periods. It peaked at 51.82% on September 30, 2021, and decreased to 31.11% by December 31, 2024.
Overall, while the company has generally maintained healthy profitability margins, there were notable fluctuations in the margins over the periods analyzed. It is important for Regeneron Pharmaceuticals Inc to carefully monitor and manage its profitability ratios to ensure sustained financial health and performance in the future.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 10.57% | 10.61% | 10.82% | 11.21% | 12.23% | 13.12% | 14.14% | 14.73% | 16.22% | 22.52% | 25.20% | 34.51% | 35.18% | 31.57% | 31.09% | 22.45% | 20.84% | 19.18% | 19.20% | 15.42% |
| Return on assets (ROA) | 11.69% | 12.43% | 11.98% | 11.22% | 11.95% | 12.41% | 14.02% | 13.91% | 14.85% | 19.40% | 20.90% | 30.11% | 31.75% | 29.55% | 28.88% | 22.53% | 20.47% | 19.62% | 20.68% | 14.46% |
| Return on total capital | 12.62% | 13.20% | 13.52% | 14.20% | 15.28% | 16.55% | 18.63% | 18.52% | 19.96% | 26.02% | 28.23% | 41.97% | 45.22% | 42.13% | 42.67% | 31.96% | 29.74% | 29.12% | 36.17% | 21.27% |
| Return on equity (ROE) | 15.03% | 15.87% | 15.32% | 14.29% | 15.22% | 16.03% | 17.90% | 17.80% | 19.14% | 25.05% | 27.49% | 39.84% | 43.03% | 40.53% | 41.02% | 33.43% | 31.86% | 31.17% | 32.94% | 18.79% |
Regeneron Pharmaceuticals Inc's profitability ratios show a generally positive trend over the period under review. The Operating return on assets (Operating ROA) increased steadily from 15.42% as of March 31, 2020, peaking at 35.18% by December 31, 2021. However, there was a gradual decline thereafter to 10.57% by December 31, 2024.
Similarly, the Return on assets (ROA) exhibited an upward trajectory, rising from 14.46% on March 31, 2020, to a peak of 31.75% on December 31, 2021. Subsequently, it experienced a downward trend, reaching 11.69% by December 31, 2024.
The Return on total capital peaked at 45.22% on December 31, 2021, following a positive trajectory from 21.27% on March 31, 2020. However, like the other ratios, it declined over the latter part of the period, ending at 12.62% by December 31, 2024.
Lastly, the Return on equity (ROE) also portrayed a similar pattern, reaching a high of 43.03% on December 31, 2021, after starting at 18.79% on March 31, 2020. The ratio then decreased steadily to 15.03% by December 31, 2024.
Overall, the profitability ratios of Regeneron Pharmaceuticals Inc reflect a positive performance in the initial years of the period but experienced a decline in later years, which could be an area of concern for investors and stakeholders.
See also:
Regeneron Pharmaceuticals Inc Profitability Ratios (Quarterly Data)